该词条未找到_海词词典

您要查找的是不是：

Keywords Enzyme stability;Urine plasminogen activator;Glycosylation; 酶稳定性;尿纤溶酶原激活物;糖基化;
urine plasminogen activator 尿纤溶酶原激活物, 尿激酶
THE EXPRESSION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN ORAL SQUAMOUS CELL CARCINOMA. 尿激酶受体在口腔鳞癌中的表达。
Recombinant tissue-type plasminogen activator (r-TPA) was also used when clinically indicated. 临床上有指征时也可应用重组组织型纤溶酶原激活剂。
In this process, urokinase-type plasminogen activator(uPA) and P-selectin play a very important role . 在此过程中，尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator，uPA)和P-选择素起着十分重要的作用。
PURPOSE:To establish a stable cell strain secreted recombinant tissue-type plasminogen activator(rt-PA). 目的:建立稳定表达人组织型纤溶酶原激活剂(tissue-type plasminogen activatort-PA)的细胞系。
Enzymatic Vitreolysis with Recombinant Microplasminogen and Tissue Plasminogen Activator. Chen W（陈武）; Huang X; Ma XW; et al.
The recombinant human urinary plasminogen activator (RHU-PA) is a thrombolytic agent. 重组人糖基化尿型纤溶酶原激活剂(RHU-PA)是一种溶血栓药物。
Objective:To examine whether VLDL or LDL can stimulate the secretion of plasminogen activator inhibitor type 1 (PAI-1) in hepatic cells. 目的 :观察极低密度脂蛋白 (VL DL)与低密度脂蛋白 (L DL)是否能刺激肝细胞纤溶酶原激活物抑制物 - 1(PAI- 1)的分泌。
Hacke W, Kaste M, Fieschi C. Intrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA, 1995, 247 (13):1017. 郑家生;崔雄伟;赵永春;等.;急性缺血性脑卒中超选择动脉溶栓疗法的并发症分析
BAL b/c mice were immunized by injections of human tissue-type plasminogen activator (t-PA) purified from human melanoma cells and pig heart. 用猪心t-PA和人黑色素瘤细胞分泌的t-PA作抗原,经腹腔及脾内免疫Bal b/c小鼠。
Objective To investigate the anticoagulative and fibrinolytic effects of lumbrokinase and their relation to tissue plasminogen activator (t-PA). 目的探讨蚓激酶抗凝、纤溶机制及其与组织型纤溶酶原激活剂(t-PA)的关系。
Tissue plasminogen activator, for example, can be given within 3 hours of a stroke, and similar treatments are being developed for ICH. 例如，可在中风发生后的3小时内对病人给予组织纤溶酶原激活物进行治疗，对脑出血病人，类似的治疗手段也在开展当中。
A stroke drug known as tPA, or tissue plasminogen activator, has been a lightning rod since it was first approved in the United States in 1996. 自从1996年在美国被发现以来，已经成为中风的“避雷针”。
Objective: To identify the significance of urokinase-type plasminogen activator(UPA) expression in patients with epithelial ovarian carcinoma. 目的:探讨尿激酶型纤溶酶原激活因子(UPA)的蛋白表达与上皮性卵巢癌生物学行为的关系。
Plasminogen activator(PA) and plasminogen activator inhibitor(PAI) are involved in many physiological or pathological events. 纤溶酶原激活因子(PA)及其抑制因子(PAI)参与机体的多种生理、病理活动。
Objective To investigate the expression and role of urokinase-type plasminogen activator(uPA) in the invasion and metastasis of NPC. 目的探讨尿激酶型纤溶酶原激活剂在鼻咽癌组织中的表达及其与鼻咽癌侵袭和转移的关系。
With that information,they determined it was safe to go ahead and give him tPA (tissue plasminogen activator),the same clotbusting drug used to stop heart attacks. 掌握了这些情况，医生们断定可以安全地继续进行治疗。他们给库比兹使用tPA(组织血浆酶原激活剂)。这种冲破血栓的药剂也用于治疗心脏病。
Objective To investigate the direct effects of various fatty acids on expression of plasminogen activator inhibitor-1 (PAI-1) in human endothelial cells (ECs). 目的探讨不同脂肪酸对血管内皮细胞(ECs)纤溶酶原激活物抑制剂-1(PAI-1)表达的直接影响及影响水平。
The effect of Pentainidine lsethionate(PI)on tissue plasminogen activator(tPA),plasmin(Pli)and plasminogen(Plg)in vitro were compared with tranexamic acid(AMCA). 对羟乙酸戊烷脒（PI）对组织型纤溶酶元激活因子（t－PA），纤溶酶元（Plg）及纤溶酶（Pli）的作用进行体外测定，并与止血环酸（AMCA）的作用进行比较。